Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed
Surveys, Registries, Interviews
Registry for with an inherited mutation or cancer in the family
Clinicaltrials.gov identifier:NCT03231891
Study Contact Information:
Tuya Pal, MD, FACMG
Principal Investigator
Email: [email protected]
Phone: 615-875-2444
About the Study
ICARE is a registry of individuals interested in participating in research, through which data and samples are collected to contribute to research. Participants are also provided with ongoing research and clinical updates and informed about other research opportunities for which they might be eligible. Participants are recruited across the United States and beyond. There is no cost to participate, and all materials can be completed online. To enroll into ICARE, please visit https://redcap.link/ICAREconsent.
This Study is Open To:
People who carry an in a gene linked to cancer, as well as patients with an unexplained strong personal and/or family history of cancer.
This Study is NOT Open To:
People under the age of 18.
What the Study Involves
Through ICARE, individuals interested in participating in studies focused on predisposition are recruited to a registry. Participants include individuals who carry a mutation (i.e., pathogenic or likely pathogenic variant) and/or () in an gene, as well as patients with an unexplained strong personal and/or family history of cancer. There is no cost to participate, and all materials can be completed online.
Participation involves completing an online consent, medical records and tissue/tumor release forms, as well as an initial and follow-up surveys. Saliva and/or tumor samples may also be requested from participants to conduct additional genomic analyses.
Additionally, participants are sent information about targeted research efforts for which they may be eligible. For example, we currently have various research efforts underway, including:
- risks and treatment outcomes among individuals with multiple cancer types and a mutation in high (, , ) and moderate risk (, , , ) genes.
- breast cancers in women with , , , , and mutations through doing tumor , to learn more about how we might best treat them.
Lead Researcher
Tuya Pal, MD, FACMG
Principal Investigator
Vanderbilt University Medical Center
Vanderbilt-Ingram Cancer Center
Study Contact Information:
Tuya Pal, MD, FACMG
Principal Investigator
Email: [email protected]
Phone: 615-875-2444
Locations:
Tennessee
City: Nashville RECRUITING
Facility: Vanderbilt-Ingram Cancer Center
Contact Info:
[email protected]
615-875-2444
Tuya Pal, MD
Surveys, Registries, Interviews
Registry for with an inherited mutation or cancer in the family
Clinicaltrials.gov identifier:NCT03231891
Study Contact Information:
Tuya Pal, MD, FACMG
Principal Investigator
Email: [email protected]
Phone: 615-875-2444